Pathophysiology and Management of Acute Coronary Syndromes

Published Online: Monday, March 25, 2013
Follow Pharmacy_Times:
In this podcast from the BMJ Group, Mark de Belder, MD, a consultant cardiologist, speaks to James McLenachan, MRCP, a fellow consultant cardiologist, and Keith Channon, MD, professor of cardiovascular medicine at the University of Oxford, about the pathophysiology and management of acute coronary syndromes. To listen to the podcast online, click here. To download it, click here.
Related Articles
Live medication therapy management (MTM) reduces low-density-lipoprotein cholesterol significantly more than standard, chart-review MTM.
The results of an FDA safety review of omalizumab (Xolair) suggest the asthma drug slightly elevates the risk of serious cardiovascular and cerebrovascular adverse events.
A starter pack of Janssen Pharmaceuticals’ rivaroxaban (Xarelto) will be available at pharmacies starting in October 2014.
In a Phase 3 study, odanacatib significantly reduced the risk of osteoporotic fractures, but it also might have contributed to major cardiovascular events.
Latest Issues
$auto_registration$